United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $484.23, for a total value of $1,936,920.00. Following the completion of the transaction, the chief executive officer owned 130 shares of the company’s stock, valued at $62,949.90. The trade was a 96.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

United Therapeutics Stock Down 2.0%

UTHR traded down $9.80 during trading on Monday, reaching $479.51. 468,634 shares of the company’s stock were exchanged, compared to its average volume of 581,703. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $492.62. The business has a 50 day moving average price of $452.91 and a 200 day moving average price of $368.72. The company has a market capitalization of $20.65 billion, a P/E ratio of 18.17, a PEG ratio of 4.86 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same quarter in the prior year, the company posted $6.39 EPS. The business’s revenue was up 6.8% on a year-over-year basis. As a group, research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently modified their holdings of UTHR. Wilmington Savings Fund Society FSB increased its holdings in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares in the last quarter. Chung Wu Investment Group LLC bought a new position in United Therapeutics in the 2nd quarter valued at $29,000. Abich Financial Wealth Management LLC acquired a new stake in shares of United Therapeutics in the 3rd quarter valued at $44,000. SVB Wealth LLC acquired a new stake in shares of United Therapeutics in the 1st quarter valued at $32,000. Finally, WealthCollab LLC raised its position in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. HC Wainwright lifted their price objective on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Royal Bank Of Canada boosted their price target on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Morgan Stanley set a $447.00 price target on United Therapeutics in a research report on Wednesday, October 29th. Wells Fargo & Company lifted their price objective on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a report on Wednesday, November 19th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.